Don't miss this roundtable! Jane will do a great job in leading a scintillating discussion and debate.
🔬🚀 Don't Miss the Battle of Biologics Modalities! 🧬🧪 We are excited to extend an invitation to the highly anticipated roundtable discussion, "The Battle of Biologics Modalities," scheduled for September 23, 2024, from 16:05-17:05 during the Emerging Technologies Track at the Antibody Therapeutics Xchange - San Francisco 2024. SECURE YOUR COMPLIMENTARY PASS TODAY https://lnkd.in/e4bWB39F 🧫 Key Discussion Topics Include: 🟡 Single Domain Antibodies vs scFvs 🔄 – Delving into the advantages and limitations in discovery platforms, reformatting, and physicochemical properties. 🟡 Common Light Chain Discovery 🧠 – Analyzing the key risk factors for a successful campaign. 🟡 T-cell Engagers vs CARs, ADCs vs Radiolabeled Antibodies ⚔️ – Who will emerge victorious? Let’s explore this dynamic debate. 🎤 Industry Expert: Jane Seagal Jane Seagal, Vice President of Antibody Discovery at Ablexis, LLC and AlivaMab Biologics will lead this insightful discussion. With over a decade of experience in antibody drug discovery, Jane's expertise in in vivo approaches and her innovative work at AbbVie make her the perfect guide through these critical topics. Ensure you don’t miss this unique opportunity to gain insights from a leader in the field and engage in a lively discussion with fellow professionals. 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 🧬 Let’s shape the future of biologics together! #Biologics #AntibodyTherapeutics #EmergingTechnologies #Biotech #SanFrancisco2024 #HealthcareInnovation #Biopharma #LifeSciences #AntibodyEngineering #DrugDiscovery #Immunotherapy #Biotechnology #PharmaInnovation #MedicalResearch #TherapeuticDevelopment #ClinicalResearch #HealthTech #PrecisionMedicine #BiotechIndustry #InnovationInMedicine #NextGenTherapeutics #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass
